Literature DB >> 25332315

Laboratory evaluation of pheochromocytoma and paraganglioma.

Graeme Eisenhofer1, Mirko Peitzsch2.   

Abstract

BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are potentially lethal yet usually surgically curable causes of endocrine hypertension; therefore, once clinical suspicion is aroused it is imperative that clinicians choose the most appropriate laboratory tests to identify the tumors. CONTENT: Compelling evidence now indicates that initial screening for PPGLs should include measurements of plasma free metanephrines or urine fractionated metanephrines. LC-MS/MS offers numerous advantages over other analytical methods and is the method of choice when measurements include methoxytyramine, the O-methylated metabolite of dopamine. The plasma test offers advantages over the urine test, although it is rarely implemented correctly, rendering the urine test preferable for mainstream use. To ensure optimum diagnostic sensitivity for the plasma test, reference intervals must be established for blood samples collected after 30 min of supine rest and after an overnight fast when measurements include methoxytyramine. Similarly collected blood samples during screening, together with use of age-adjusted reference intervals, further minimize false-positive results. Extents and patterns of increases in plasma normetanephrine, metanephrine, and methoxytyramine can additionally help predict size and adrenal vs extraadrenal locations of tumors, as well as presence of metastases and underlying germline mutations of tumor susceptibility genes.
SUMMARY: Carried out correctly at specialist endocrine centers, collection of blood for measurements of plasma normetanephrine, metanephrine, and methoxytyramine not only provides high accuracy for diagnosis of PPGLs, but can also guide clinical decision-making about follow-up imaging strategies, genetic testing, and therapeutic options. At other centers, measurements of urine fractionated metanephrines will identify most PPGLs.
© 2014 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25332315     DOI: 10.1373/clinchem.2014.224832

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  32 in total

Review 1.  The role of miRNAs in the pheochromocytomas.

Authors:  Zheng Li; Xin Yu; Jianxiong Shen
Journal:  Tumour Biol       Date:  2015-10-13

Review 2.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

3.  Heart combined with adrenal multiple pheochromocytomas.

Authors:  Su-Hong Zhao; Shuang Liang; Jing Luo; Hong-Dan Mo; Yu Jiang; Mao-Mao Zhang; Jie Yuan
Journal:  J Nucl Cardiol       Date:  2017-06-07       Impact factor: 5.952

Review 4.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 5.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

6.  PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.

Authors:  Maria Currás-Freixes; Elena Piñeiro-Yañez; Cristina Montero-Conde; María Apellániz-Ruiz; Bruna Calsina; Veronika Mancikova; Laura Remacha; Susan Richter; Tonino Ercolino; Natalie Rogowski-Lehmann; Timo Deutschbein; María Calatayud; Sonsoles Guadalix; Cristina Álvarez-Escolá; Cristina Lamas; Javier Aller; Julia Sastre-Marcos; Conxi Lázaro; Juan C Galofré; Ana Patiño-García; Amparo Meoro-Avilés; Judith Balmaña-Gelpi; Paz De Miguel-Novoa; Milagros Balbín; Xavier Matías-Guiu; Rocío Letón; Lucía Inglada-Pérez; Rafael Torres-Pérez; Juan M Roldán-Romero; Cristina Rodríguez-Antona; Stephanie M J Fliedner; Giuseppe Opocher; Karel Pacak; Esther Korpershoek; Ronald R de Krijger; Laurent Vroonen; Massimo Mannelli; Martin Fassnacht; Felix Beuschlein; Graeme Eisenhofer; Alberto Cascón; Fátima Al-Shahrour; Mercedes Robledo
Journal:  J Mol Diagn       Date:  2017-05-25       Impact factor: 5.568

7.  In vivo detection of catecholamines by magnetic resonance spectroscopy: A potential specific biomarker for the diagnosis of pheochromocytoma.

Authors:  Alessio Imperiale; Stephanie Battini; Gerlinde Averous; Didier Mutter; Bernard Goichot; Philippe Bachellier; Karel Pacak; David Taïeb; Izzie-Jacques Namer
Journal:  Surgery       Date:  2015-05-01       Impact factor: 3.982

Review 8.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

Review 9.  Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options.

Authors:  Karren Antonio; Ma Margarita Noreen Valdez; Leilani Mercado-Asis; David Taïeb; Karel Pacak
Journal:  Gland Surg       Date:  2020-02

Review 10.  Endocrine causes of hypertension in pregnancy.

Authors:  Alison H Affinati; Richard J Auchus
Journal:  Gland Surg       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.